Carl-Magnus Högerkorp MSc, PhD, Executive MBA, has more than 20 years of experience in R&D from academia, big pharma and small life science innovation companies. Previous roles as CEO of Edvince AB, CSO at Xintela AB and research positions at Novo Nordisk and the National Institutes of Health, USA. Carl-Magnus has a comprehensive understanding of the whole drug development value chain in areas of oncology, autoimmune disease, chronic inflammatory disease, regenerative medicine, stroke and infectious disease. He has an MBA specialized in life science innovation strategies and PhD in immunology/immunotechnology.
Founder of CanImGuide Therapeutics based on his own innovations. Focused on managing the scientific agenda, the IP strategy and plan and scientific communication around this project. Dr Håkansson’s research include immune parameters of importance for response, monitoring and optimization of immunotherapy and biochemotherapy in various types of cancer, e.g. renal cell carcinoma, malignant melanoma and colorectal cancer. He has published more than 75 peer-reviewed articles, given approximately 40 congress presentations on these and other topics, and holds several patents on methods for the prediction and monitoring of immunotherapy of cancer.
Anette Sundstedt has almost 20 years of experience in research and development in the pharmaceutical/biotech industry with a major focus in immunology and immunotherapy. Previous roles as CSO of Idogen AB and senior research positions at Active Biotech AB and the University of Bristol. Anette has extensive experience of scientific leadership both as project leader and as a project team member with the responsibility for leading biological and pharmacological research in pre-clinical and clinical immune-oncology projects. She holds a M.Sc. in cellular and molecular biology and a Ph.D. in tumor immunology from Lund University.